Evotec SEEVO +1.11%64 PB Ratio is 1.20 as of Jun. 26, 2026, which is 74% below its 10-year median of 4.63. GuruFocus rates EVO with a GF Score™ of 64/100 and a GF Value™ of $4.27 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 922 Drug Manufacturers companies, Evotec SE ranks better than 67.35% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), Evotec SE's share price is $2.74. Evotec SE's Book Value per Share for the quarter that ended in Mar. 2026 was $2.28. Hence, Evotec SE's PB Ratio of today is 1.20.
The historical rank and industry rank for Evotec SE's PB Ratio or its related term are showing as below:
EVO'
s PB Ratio Range Over the Past 10 Years
Min: 0.91 Med: 4.63 Max: 9.81
Current: 1.24
During the past 13 years, Evotec SE's highest PB Ratio was 9.81. The lowest was 0.91. And the median was 4.63.
EVO's PB Ratio is ranked better than 67.35% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs EVO: 1.24
During the past 12 months, Evotec SE's average Book Value Per Share Growth Rate was -23.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -11.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -2.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 16.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Evotec SE was 39.90% per year. The lowest was -25.60% per year. And the median was 5.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Evotec SE PB Ratio Related Terms
Evotec SE PB Ratio Historical Data
* Premium members only.
The historical data trend for Evotec SE's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Evotec SE's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evotec SE PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evotec SE's PB Ratio distribution charts can be found below:
* The bar in red indicates where Evotec SE's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Evotec SE's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Evotec SE (EVO) has a PB Ratio of 1.20 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Evotec SE and its competitors. This is 74% below median its historical median of 4.63. Over the past decade, Evotec SE's PB Ratio has ranged from 0.91 to 9.81. According to the industry distribution chart, Evotec SE ranks #301 out of 922 companies in the Drug Manufacturers industry, placing it in the top 32.6%.
Is Evotec SE's PB Ratio too high?
Evotec SE's current PB Ratio of 1.20 is 74% below median its 10-year median of 4.63. Over the past 10 years, this metric has ranged from a low of 0.91 to a high of 9.81. The Drug Manufacturers industry median PB Ratio is 1.83. Evotec SE's value of 1.20 is 34.2% below this industry median. Based on the distribution chart, Evotec SE ranks #301 out of 922 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Evotec SE has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evotec SE's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Evotec SE ranks #301 out of 922 companies for PB Ratio. This puts Evotec SE in the upper half of its industry. The industry median PB Ratio is 1.83. Evotec SE's value of 1.20 is 34.2% below this benchmark. Historically, Evotec SE's own PB Ratio has ranged from 0.91 to 9.81 over the past decade. While the company's 10-year median is 4.63 vs. the industry median of 1.83, Evotec SE has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Evotec SE's current PB Ratio of 1.20 is 34.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Evotec SE and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evotec SE's current PB Ratio is 1.20, which is 74% below median its own 10-year median of 4.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evotec SE stock overvalued right now?
Based on GuruFocus' analysis, Evotec SE (EVO) is currently considered Possible Value Trap. The stock's GF Value™ is $4.27, compared to a current price of $2.74 — trading 35.8% below its estimated fair value. The current PB Ratio is 1.20, which is 74% below median its 10-year median of 4.63 and 34.2% below the Drug Manufacturers industry median of 1.83. Evotec SE's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Evotec SE (EVO), the current PB Ratio is 1.20 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evotec SE (EVO) Overvalued in 2026?
Based on GuruFocus' analysis, Evotec SE stock appears to be undervalued.
The current stock price of $2.74 is trading 35.8% below its estimated GF Value™ of $4.27.
GuruFocus considers Evotec SE to be Possible Value Trap.
Key valuation signals for EVO:
PB Ratio: 1.20 (74% below median its 10-year median of 4.63)
GF Value™: $4.27 vs. price of $2.74 (35.8% below fair value)
Industry Position: 34.2% below the Drug Manufacturers median (#301 of 922)
No single metric tells the full story. See the EVO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.
64GF Score
Get the complete analysis for EVO
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVO has been successfully added to your 
